Clin Exp Pediatr.
2021 Dec;64(12):602-607. 10.3345/cep.2021.00507.
Recommendation for use of diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate, and hepatitis B vaccine in infants
- Cho HK1
- Park SE2
- Kim YJ3
- Jo DS4
- Kim YK5
- Eun BW6
- Lee TJ7
- Lee J8
- Lee H9
- Kim KH10
- Cho EY11
- Ahn JG12
- Choi EH
9 - The Committee on Infectious Diseases of the Korean Pediatric Society1
- Affiliations
-
- 1Department of Pediatrics, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
- 2Department of Pediatrics, School of Medicine, Pusan National University, Pusan, Korea
- 3Department of Pediatrics, Sungkyunkwan University School of Medicine, Suwon, Korea
- 4Department of Pediatrics, Jeonbuk National University Medical School, Jeonju, Korea
- 5Department of Pediatrics, Korea University College of Medicine, Seoul, Korea
- 6Department of Pediatrics, School of Medicine, Eulji University, Daejeon, Korea
- 7Department of Pediatrics, CHA University School of Medicine, Pocheon, Korea
- 8Department of Pediatrics, University of Ulsan College of Medicine, Ulsan, Korea
- 9Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea
- 10Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 11Department of Pediatrics, Chungnam National University School of Medicine, Daejeon, Korea
- 12Department of Pediatrics, Severance Children’s Hospital, Yonsei University College of Medicine, Seoul, Korea
- KMID: 2522659
- DOI: http://doi.org/10.3345/cep.2021.00507
Abstract
- In April 2020, the Ministry of Food and Drug Safety licensed a hexavalent combined diphtheria and tetanus toxoids and acellular pertussis (DTaP), inactivated poliovirus (IPV), Haemophilus influenzae type b (Hib) conjugated to tetanus protein, and hepatitis B (HepB) (recombinant DNA) vaccine, DTa-PIPV-Hib-HepB (Hexaxim, Sanofi Pasteur), for use as a 3-dose primary series in infants aged 2, 4, and 6 months. The DTaP-IPVHib-HepB vaccine is highly immunogenic and safe and provides a long-term immune response based on studies performed in a variety of settings in many countries, including Korea. This report summarizes the Committee on Infectious Diseases of the Korean Pediatric Society guidelines for the use of this newly introduced hexavalent combination vaccine.
